Cell penetrating peptide-functionalized small interfering RNA nanoparticles knock down HER expression in breast cancer cells.

Ranga Dissanayake, Vineet Kumar Mishra, Marya Ahmed

Abstract read

In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ranga DissanayakeDepartment of Chemistry, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada.

Vineet Kumar MishraDepartment of Chemistry, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada.

Marya AhmedDepartment of Chemistry, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada; Faculty of Sustainable Design Engineering, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada. Electronic address: marahmed@upei.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efficient delivery of small interfering RNA (siRNA) remains a major challenge in gene therapy, particularly due to poor cellular uptake, enzymatic degradation, and endosomal entrapment of the cargo. Cell penetrating peptides (CPPs) offer a promising strategy for intracellular delivery of nucleic acids; however, peptide-based gene delivery carriers possess limited nucleic acid condensation capability, demonstrating reduced transfection efficacies in mammalian cells. This study aimed to enhance siRNA delivery efficacies of CPP-based siRNA therapeutics by combining nucleic acid condensation efficacies of methylated protamine with the cell permeation capabilities of cyclic peptides to improve physiological stability, cellular uptake, and gene silencing efficacies in HER2

Indexed as

Breast NeoplasmsCell-Penetrating PeptidesErb-b2 Receptor Tyrosine KinasesGene Knockdown TechniquesNanoparticlesRNA, Small InterferingCell Line, TumorFemaleGene SilencingHumansMCF-7 CellsCell-Penetrating PeptidesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRNA, Small InterferingAnticancer therapeuticsCell penetrating peptide–functionalized nanoparticlesPhysiological stabilitySmall interfering RNA delivery

Identifiers

PMID41478672

DOI10.1016/j.jpet.2025.103697

PMCPMC12799534

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.